ImpediMed (IPD) Q2 2025 TU earnings summary

Executive summary

• Achieved record Q2 FY25 revenue of AUD 3.3 million, up 24% quarter-on-quarter and 46% year-over-year, with record cash receipts and improved operating cash outflow.

• SOZO unit sales rose 75% quarter-on-quarter to 49 units, with a 112% year-over-year pipeline increase and growing clinical adoption.

• Reimbursed covered lives expanded to 258.5 million, with 25 U.S. states above 80% coverage and 11 of the top 15 payors now reimbursing.

• Renewed top 10 client with a 35% price increase; average renewal price up 23%.

• Cash balance at 30 June 2024 was AUD 17.7 million, funding 7.2 quarters of operations (5.2 quarters excluding R&D tax credit).

Financial highlights

• Record quarterly revenue of AUD 3.3 million and cash receipts of AUD 3.4 million, with operating cash outflow reduced to AUD 2.5 million.

• Annual Recurring Revenue (ARR) reached AUD 12.5 million, up 23% year-on-year.

• Total Contract Value (TCV) for the quarter was AUD 3.2 million, down from AUD 4.8 million in Q4 FY24.

• Cash expenditure reduced by 10% vs FY24; staff costs were the largest outflow at AUD 4.5 million.

• Churn remained low at 3% per annum.

Outlook and guidance

• Next quarter focus: accelerate sales pipeline conversion, expand private payer coverage, and maintain cost control.

• Net operating cash outflows (excluding R&D tax credit) expected to remain below AUD 3.5 million.

• Management confident in achieving break-even with current pipeline and reimbursement trends.

• Product roadmap finalization and measured investment in sales resources planned.